Bruker Corporation (NASDAQ:BRKR) Receives Average Rating of “Hold” from Brokerages

Bruker Corporation (NASDAQ:BRKR) has earned a consensus recommendation of “Hold” from the eleven research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $51.00.

Several analysts recently commented on BRKR shares. Wells Fargo & Company decreased their price target on Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 5th. Barclays reduced their price objective on Bruker from $43.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday. Bank of America reduced their price objective on Bruker from $61.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, June 26th. Stifel Nicolaus set a $40.00 price objective on Bruker and gave the stock a “hold” rating in a research note on Tuesday, August 5th. Finally, Citigroup reduced their price objective on Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research note on Monday, August 4th.

Bruker Price Performance

Shares of BRKR stock opened at $36.98 on Monday. The stock’s fifty day simple moving average is $33.51 and its 200 day simple moving average is $37.41. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. The firm has a market cap of $5.61 billion, a price-to-earnings ratio of 71.12, a P/E/G ratio of 5.14 and a beta of 1.20. Bruker has a one year low of $28.53 and a one year high of $67.42.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. Bruker’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, analysts expect that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd were paid a $0.05 dividend. The ex-dividend date of this dividend was Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s payout ratio is currently 38.46%.

Insider Activity

In other news, Director Cynthia M. Friend sold 3,535 shares of the company’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director owned 18,016 shares of the company’s stock, valued at $581,016. This represents a 16.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 27.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bruker

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC increased its holdings in Bruker by 377.5% in the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 487 shares during the last quarter. Pinnacle Bancorp Inc. bought a new stake in Bruker in the first quarter valued at about $29,000. Allworth Financial LP increased its holdings in Bruker by 92.4% in the first quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 364 shares during the last quarter. Huntington National Bank increased its holdings in Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 645 shares during the last quarter. Finally, Spire Wealth Management bought a new stake in Bruker in the second quarter valued at about $32,000. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.